资讯
Blood Cancer Journal - Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis ...
A new role of STAT5B in B cell differentiation and B-ALL. Left: Physiological STAT5B level. The pre-BCR signaling cascade induces NF-κB binding.NF-κB upregulates IKAROS, which recruits the ...
3 天
News Medical on MSNTimepoint at which B cells transform into leukemic cells impacts treatment outcomesNew findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...
New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...
A new study shows that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...
Scientists at St. Jude Children’s Research Hospital and University Health Network showed that the stage of B-cell development ...
It affects the B cell lymphocytes. Around 75 out of every 100 people with ALL (around 75%) are this type. B cell ALL can be further divided into subgroups, the most common subgroup is precursor B cell ...
Kopmar NE, Quach K, Gooley TA, et al. Dose-adjusted EPOCH plus inotuzumab ozogamicin in adults with relapsed or refractory B-cell ALL: a phase 1 dose-escalation trial. JAMA Oncol. Published online ...
Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL — 3-year disease-free survival rate was 96% with blinatumomab versus 87.9% with chemo alone.
How pre- and postnatal B-12 vitamins improve breast milk vitamin B-12 levels, which supports infant brain development. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases ...
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based on findings from the FELIX trial. The Food and Drug Administration (FDA) ...
Did non-relapse mortality rates vary by CAR T cell therapy product and how may this inform treatment choice? Yes. Among patients with large B cell lymphoma, we found a higher NRM rate of 7.4% in ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果